Obesity drug mania takes over Amgen's earnings call
BioPharma
Source: biopharmadive.com
Page 9 - Jay Bradner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jay Bradner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jay Bradner Today - Breaking & Trending Today
Drugmakers Plot Way Into Obesity Market With Deals and Development
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...
Source: medscape.com
Drugmakers plot way into obesity market with deals and development
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's Wegovy and Zepbound from Eli Lilly. Amgen has an experimental dual mechanism obesity drug in mid-stage trials it hopes will have fewer side effects with less frequent dosing than Wegovy or Zepbound, Chief Scientific Officer Jay Bradner told Reuters at the annual JPMorgan health conference in San Francisco this week.
Source: yahoo.com
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance - Amgen (NASDAQ:AMGN)
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Source: benzinga.com
Weight loss drug windfall attracts pharma companies
Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's...
Source: marketscreener.com